Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineNo recent work listed

Peng Cao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2044-3074; OpenAlex author ID A5047259641. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
16
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers

Papers 8

  1. Azeliragon inhibits PAK1 and enhances the therapeutic efficacy of AKT inhibitors in pancreatic cancer. Last author DOI 10.1016/j.ejphar.2023.175703↗
  2. Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer. Co-author DOI 10.1186/s12885-023-11239-w↗
  3. Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cells. Last author DOI 10.3390/molecules27092747↗
  4. M2 Macrophage-Derived Exosomes Promote Angiogenesis and Growth of Pancreatic Ductal Adenocarcinoma by Targeting E2F2. Co-author DOI 10.1016/j.ymthe.2020.11.024↗
  5. Identification of a novel PAK1 inhibitor to treat pancreatic cancer. Last author DOI 10.1016/j.apsb.2019.11.015↗
  6. Which is the optimal adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma?: A protocol for a network meta-analysis of randomized controlled tria… Co-author DOI 10.1097/md.0000000000015761↗
  7. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, an… Co-author DOI 10.1186/s13014-019-1330-0↗
  8. Digitoflavone inhibits IκBα kinase and enhances apoptosis induced by TNFα through downregulation of expression of nuclear factor κB-regulated gene products in … Last author DOI 10.1371/journal.pone.0077126↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuhan Yang · 3 shared papers, 2020–2023 · strength 0.38
  2. Wenjing Ji · 2 shared papers, 2022–2023 · strength 0.33
  3. Xueting Cai · 3 shared papers, 2013–2023 · strength 0.31
  4. Zengya Guo · 2 shared papers, 2021–2023 · strength 0.28
  5. Chen Huang · 2 shared papers, 2021–2023 · strength 0.28
  6. Zhengjun Qiu · 2 shared papers, 2021–2023 · strength 0.28
  7. Qiancheng Hu · 2 shared papers, 2019 · strength 0.23
  8. Weikang Kong · 1 shared paper, 2023 · strength 0.17
  9. Haitao Gu · 1 shared paper, 2023 · strength 0.16
  10. Xuan Han · 1 shared paper, 2023 · strength 0.16
  11. Buwei Teng · 1 shared paper, 2021 · strength 0.12
  12. Xiaofeng Wang · 1 shared paper, 2021 · strength 0.12
  13. Dan Cao · 1 shared paper, 2019 · strength 0.11
  14. Dan Cao · 1 shared paper, 2019 · strength 0.11
  15. Ye Chen · 1 shared paper, 2019 · strength 0.11
  16. Jiaqi Wang · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.